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Objectives We aimed to compare the long-term clinical outcomes of patients treated with sirolimus-eluting stents (SES) or
paclitaxel-eluting stents (PES) for coronary bifurcation lesions.
Background There are limited data regarding comparisons of SES and PES for the treatment of bifurcation lesions.
Methods Patients who received percutaneous coronary intervention for non-left main bifurcation lesions were enrolled
from 16 centers in Korea between January 2004 and June 2006. We compared major adverse cardiac events
(MACE [cardiac death, myocardial infarction, or target lesion revascularization]) between the SES and PES
groups in patients overall and in 407 patient pairs generated by propensity-score matching.
Results We evaluated 1,033 patients with bifurcation lesions treated with SES and 562 patients treated with PES. The
median follow-up duration was 22 months. Treatment with SES was associated with a lower incidence of MACE
(hazard ratio [HR]: 0.53, 95% confidence interval [CI]: 0.32 to 0.89, p  0.01) and target lesion revasculariza-
tion (HR: 0.55, 95% CI: 0.31 to 0.97, p  0.02), but not of cardiac death (HR: 2.77, 95% CI: 0.40 to 18.99,
p  0.62) and cardiac death or myocardial infarction (HR: 0.97, 95% CI: 0.38 to 2.49, p  0.94). After
propensity-score matching, patients with SES still had fewer MACE and target lesion revascularization incidences
than did patients with PES (HR: 0.52, 95% CI: 0.30 to 0.91, p  0.02, and HR: 0.48, 95% CI: 0.25 to 0.91,
p  0.02, respectively). There was no significant difference in the occurrences of stent thrombosis between the
groups (0.7% vs. 0.7%, p  0.94).
Conclusions In patients with bifurcation lesions, the use of SES resulted in better long-term outcomes than did the use of
PES, primarily by decreasing the rate of repeat revascularization. (Coronary Bifurcation Stenting Registry in
South Korea [COBIS]; NCT00851526) (J Am Coll Cardiol 2010;55:1743–50) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.008a
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Cirolimus-eluting stents (SES) and paclitaxel-eluting stents
PES) have been shown to markedly improve angiographic
nd clinical outcomes after percutaneous coronary interven-
ion (PCI) when compared to bare-metal stents (1,2). A
umber of studies comparing the efficacy and safety of SES
nd PES have been performed in a variety of lesion subsets
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ospital, Seoul, Korea; **Wonju Christian Hospital, Wonju, Korea; ††Ajou 2nd clinical settings (3–7), but there are limited data
omparing these 2 stents in the treatment of bifurcation
esions. Although 3 previous studies compared the clinical
utcomes of patients treated with SES or PES for
ifurcation lesions, these studies were small and under-
owered, and the data from these studies are conflicting
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SES and PES in Bifurcation Lesions April 20, 2010:1743–50(8 –10). Therefore, we sought
to compare the long-term clin-
ical outcomes after implanta-
tion of the 2 most widely avail-
able drug-eluting stent (DES)
platforms for coronary bifurca-
tion lesions using data from a
dedicated, large, multicenter
real-world registry.
Methods
Study population. The COBIS
(Coronary Bifurcation Stent) reg-
istry was a retrospective multi-
center registry dedicated to bifur-
cation lesion PCI with DES. It
included data on consecutive pa-
tients from 16 major coronary
intervention centers in Korea.
Inclusion criteria were: 1) coro-
ary bifurcation lesions treated solely with at least 1 DES
etween January 2004 and June 2006; and 2) main vessel
iameter 2.5 mm and side branch diameter 2.0 mm.
xclusion criteria were the presence of cardiogenic shock,
T-segment elevation acute myocardial infarction (MI)
ithin 48 h, life expectancy 1 year, or left main bifurca-
ion. This registry was sponsored by the Korean Society of
nterventional Cardiology. The local institutional review
oard at each hospital approved this study and waived the
equirement for informed consent for access to the each
nstitutional PCI registry.
To compare SES and PES, we selected patients in the
OBIS registry database treated solely with SES or PES.
ifurcation lesions were classified according to the Medina
lassification, in which the proximal main vessel, distal main
essel, and side branch components of the bifurcation are
ach assigned a score of 1 or 0 depending on the presence or
bsence of 50% stenosis (11).
ercutaneous coronary intervention. All patients were
dministered loading doses of aspirin (300 mg) and
lopidogrel (300 to 600 mg) or ticlopidine (500 mg)
efore the coronary intervention unless they had previ-
usly received these antiplatelet medications. Anticoag-
lation therapy during PCI was performed according to
urrent practice guidelines by the Korean Society of
nterventional Cardiology. The treatment strategy, stent-
ng techniques, and selection of DES type were all left to
he operator’s discretion. Decisions to use glycoprotein
Ib/IIIa receptor inhibitors or intravascular ultrasound
IVUS) were also made by the individual operators.
spirin was continued indefinitely. The duration of
hienopyridine treatment was also at the operator’s
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
IQR  interquartile range
IVUS  intravascular
ultrasound
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularization
TVR  target vessel
revascularizationiscretion. aollow-up and end points. Clinical, angiographic, proce-
ural, and outcome data were collected with the use of a
eb-based reporting system. Additional information was
btained by further inquiry into medical records or tele-
hone contact, if necessary. All baseline and procedural cine
oronary angiograms were reviewed and qualitatively ana-
yzed at the angiographic core laboratory in the Cardiac and
ascular Center, Samsung Medical Center, Seoul, Korea.
edina classification type 1.1.1, 1.0.1, and 0.1.1 lesions
ere defined as true bifurcation lesions.
The study end point was the occurrence of a major
dverse cardiac event (MACE) during follow-up, defined
s a composite of: 1) cardiac death; 2) MI; or 3) target
esion revascularization (TLR). All deaths were consid-
red cardiac unless a definite noncardiac cause could be
stablished. An MI was defined as elevated cardiac
nzymes (troponin or myocardial band fraction of creat-
ne kinase) more than the upper limit of the normal value
ith ischemic symptoms or electrocardiography findings
ndicative of ischemia that was not related to the index
rocedure. TLR was defined as repeat PCI of the lesion
ithin 5 mm of stent deployment or bypass graft surgery
f the target vessel. Target vessel revascularization (TVR)
as repeat revascularization of the target vessel by PCI or
ypass graft surgery. Periprocedural enzyme elevation was
efined as a rise in creatine kinase-myocardial band 3
imes the upper normal limit after the index procedure
12). The periprocedural period includes the first 48 h
fter PCI, and periprocedural enzyme elevation was not
onsidered as MACE in our study. Stent thrombosis
ST) was assessed based on the definitions of the Aca-
emic Research Consortium as definite, probable, or
ossible stent thrombosis (12). The timing of ST was
lassified as early (within 1 month after index procedure),
ate (between 1 month and 1 year), or very late (after 1
ear). All outcome data reported from the participating
enters were reviewed by an independent clinical event
djudicating committee.
tatistical analyses. Differences between the groups of
atients receiving SES and PES in baseline characteris-
ics were compared using the t test or Wilcoxon rank-sum
est for continuous variables, and the chi-square test or
isher’s exact test for categorical variables, as appropriate.
urvival curves were constructed using Kaplan-Meier
stimates and were compared with the log-rank test.
ovariates statistically significant on univariate analysis
nd/or those clinically relevant were considered as can-
idate variables in the multivariate models. Adjusted
azard rates were compared by means of Cox regression
ith age, sex, acute coronary syndrome, diabetes mellitus,
rue bifurcation, stenting techniques, final kissing balloon
nflation, use of IVUS, type of stent used, stent diameter,
nd total stent length. We also included use of clopi-
ogrel as a time-dependent covariate (assessed at 1, 3, 6,
nd 12 months) in the model.
p
m
p
m
n
l
t
b
s
g
a
g
o
W
i
B
p
o
r
i
w
p
u
2
a
S
N
R
B
1
i
y
o
A
1
B
d
a
m
S
p
s
O
M
i
p
e
m
I
d
(
P
p
o
2
w
g
d
c
C
c
B
D
1745JACC Vol. 55, No. 16, 2010 Song et al.
April 20, 2010:1743–50 SES and PES in Bifurcation LesionsTo reduce treatment-selection bias for stent type and
otential confounding, we performed rigorous adjust-
ent for baseline characteristics of patients using pro-
ensity score. The propensity scores were estimated using
ultiple logistic-regression analysis. A full nonparsimo-
ious model was developed that included all variables
isted in Tables 1 and 2. The discrimination and calibra-
ion abilities of the propensity-score model were assessed
y means of the c-statistic and the Hosmer-Lemeshow
tatistic. Cox regression analysis using pairs matched by a
reedy 5¡1 matching algorithm was also performed. We
ssessed the balance in baseline covariates between the 2
roups in a propensity score–matched cohort. Continu-
us variables were compared with a paired t test or the
ilcoxon signed-rank test, as appropriate, and categor-
cal variables were compared with the McNemar’s or
owker’s test of symmetry, as appropriate. In the pro-
ensity score–matched population, a reduction in the risk
f outcome was compared by use of a conditional Cox
egression model (13). Cumulative incidence rates of
ndividual clinical outcomes and composite outcomes
ere estimated by the Kaplan-Meier method and com-
ared by the stratified Cox regression with clopidogrel
se as a time-dependent variable. All p values are
-tailed, and p  0.05 was considered significant. All
nalyses were performed using a Statistical Analysis
oftware package (SAS version 9.1, SAS Institute, Cary,
orth Carolina).
esults
aseline characteristics. OVERALL POPULATION. Among
,919 patients registered, 251 patients did not fulfill the
aseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Total Population
PES (n  562) SES (n  1,033)
Age, yrs 61.9 10.9 62.1 10.0
Age 65 yrs 246 (43.8) 432 (41.8)
Male 366 (65.1) 703 (68.1)
Clinical presentation
Stable angina 205 (36.5) 463 (44.8)
Unstable angina 245 (43.6) 398 (38.5)
AMI 112 (19.9) 172 (16.7)
Current smoker 144 (25.6) 242 (23.4)
Diabetes mellitus 190 (33.8) 298 (28.8)
Hypertension 333 (59.3) 608 (58.9)
Dyslipidemia 180 (32.0) 316 (30.6)
Family history of CAD 21 (3.7) 41 (4.0)
Peripheral vascular disease 8 (1.4) 11 (1.1)
Prior myocardial infarction 42 (7.5) 86 (8.3)
Prior cerebrovascular event 29 (5.2) 52 (5.0)
Chronic renal failure 18 (3.2) 34 (3.3)
LVEF, %* 59.3 11.9 59.5 11.4
LVEF 50% 68 (15.4) 126 (18.1)ata are presented as mean  SD or n (%). *Left ventricular ejection fraction (LVEF) was available for 1
AMI  acute myocardial infarction; CAD  coronary artery disease; PES  paclitaxel-eluting stent(s); Snclusion criteria by core laboratory cineangiographic anal-
sis, and were excluded from the study. We also excluded
ther types of DES or mixed use of SES and PES (n 73).
total of 1,595 patients was selected in the final analysis:
,033 patients received SES and 562 patients received PES.
aseline demographic, clinical, angiographic, and proce-
ural characteristics of the 2 groups are shown in Tables 1
nd 2. The PES group had higher a prevalence of diabetes
ellitus and acute coronary syndrome on admission. In the
ES group, IVUS and final kissing balloon inflation were
erformed more frequently, and the diameter of side branch
tents implanted was larger than that of the PES group.
ther characteristics, including bifurcation site treated,
edina classification, and stenting technique, were similar
n both groups. Main vessel stenting alone was primarily
erformed in both groups. There were no significant differ-
nces in procedural characteristics such as stent type, treat-
ent strategy (1-stent vs. 2-stent), and use of glycoprotein
Ib/IIIa inhibitors among centers. However, use of IVUS
iffered significantly according to the PCI volume of centers
data not shown).
ROPENSITY-MATCHED POPULATION. After performing
ropensity-score matching for the entire population, a total
f 407 matched pairs of patients were created (Tables 1 and
). The c-statistic for the propensity score model was 0.65,
hich indicates good discrimination (Hosmer-Lemeshow
oodness of fit, p  0.78). There were no significant
ifferences in baseline clinical, angiographic, and procedural
haracteristics for the propensity-matched subjects.
linical outcomes. OVERALL POPULATION. Complete
linical follow-up data were obtained in 97.9% of all
Propensity-Matched Population
p Value PES (n  407) SES (n  407) p Value
0.72 61.9 11.2 62.2 9.9 0.66
0.45 183 (45.0) 171 (42.0) 0.40
0.23 266 (65.4) 259 (63.6) 0.61
0.01 0.87
159 (39.1) 155 (38.1)
164 (40.3) 162 (39.8)
84 (20.6) 90 (22.1)
0.33 101 (24.8) 101 (24.8) 0.99
0.04 117 (28.7) 116 (28.5) 0.94
0.88 251 (61.7) 248 (60.9) 0.83
0.55 118 (29.0) 123 (30.2) 0.70
0.82 18 (4.4) 13 (3.2) 0.36
0.53 5 (1.2) 5 (1.2) 0.99
0.55 28 (6.9) 29 (7.1) 0.89
0.91 22 (5.4) 24 (5.9) 0.76
0.92 13 (3.2) 7 (1.7) 0.17
0.80 58.7 11.4 58.9 11.4 0.88
0.24 50 (16.0) 54 (19.9) 0.21,139 patients.
ES  sirolimus-eluting stent(s).
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SES and PES in Bifurcation Lesions April 20, 2010:1743–50atients. The median follow-up was 20 months (interquar-
ile range [IQR]: 14 to 29) in the PES group and 23 months
IQR: 15 to 34) in the SES group. There were a total of 101
vents during the entire study period. The incidence of
ACE was significantly lower in patients with SES than
n those with PES (Table 3, Fig. 1A). Although both
roups had comparable incidences of cardiac death or MI,
he SES group had a significantly lower incidence of TLR
nd TVR (Table 3, Fig. 1B). Treatment strategy (single vs.
ouble stent), use of glycoprotein IIb/IIIa receptor antago-
ists, and use of IVUS did not influence the MACE in
verall patients. Multivariate analysis showed that the use of
ES was associated with significantly lower MACE and
LR rates (Table 3). The incidence of periprocedural
nzyme elevation was similar in the 2 groups (14.7% in the
ES group vs. 17.3% in the PES group, p  0.25).
Definite or probable ST was noted in 11 patients
0.7%) during the follow-up period; early ST in 6 patients
0.4%), late ST in 2 patients (0.1%), and very late ST in
ngiographic and Procedural CharacteristicsTable 2 Angiographic and Procedural Characteristics
Total Population
PES (n  562) SES (n  1,
Vessel involved
LAD/diagonal 414 (73.7) 809 (78.3
LCX/OM 113 (20.1) 175 (16.9
RCA bifurcation 35 (6.2) 49 (4.7)
Medina classification
True bifurcation 399 (71.0) 703 (68.1
1.1.1 298 (53.0) 509 (49.3
1.0.1 27 (4.8) 76 (7.4)
0.1.1 74 (13.2) 118 (11.4
Non-true bifurcation 163 (29.0) 330 (31.9
1.0.0 36 (6.4) 80 (7.7)
0.1.0 49 (8.7) 109 (10.6
1.1.0 71 (12.6) 124 (12.0
0.0.1 7 (1.2) 17 (1.6)
Stenting technique
Main vessel stenting only 472 (84.0) 850 (82.3
Stent in both branches 90 (16.0) 183 (17.7
T-stenting 42 (46.7) 86 (47.0
Crush 22 (24.4) 72 (39.3
Kissing stenting 21 (23.3) 20 (10.9
Culottes 5 (5.6) 5 (2.7)
Final kissing balloon inflation 192 (34.2) 475 (46.0
Guidance of intravascular ultrasound 148 (26.3) 370 (35.8
Use of glycoprotein IIb/IIIa inhibitor 25 (4.4) 33 (3.2)
Remote site intervention 144 (25.6) 250 (24.2
Main vessel
Total stent length (mm) 31.1 13.9 30.0 12
Maximal stent diameter (mm) 3.14 0.32 3.13 0.3
Side branch (n 90) (n 183
Total stent length (mm) 20.8 8.5 22.3 8.9
Maximal stent diameter (mm) 2.69 0.25 2.77 0.2
ata are presented as mean  SD or n (%).
LAD  left anterior descending artery; LCX  left circumflex artery; OM  obtuse marginal brapatients (0.4%). The status of dual antiplatelet therapy (as available in 97.0% of patients 1 year after the index
rocedure. The median duration of clopidogrel use was
imilar in the 2 groups (12 months [IQR: 7 to 20]) in the
ES group vs. 12 months [IQR: 7 to 19]) in the PES
roup, p  0.82). Four patients died of early ST,
lthough no cardiac deaths occurred among patients who
xperienced late or very late ST. Of patients who had
efinite or probable thrombosis, the SES group had 6 on
ual antiplatelet therapy and 1 on aspirin only, and the
ES group had 3 patients on dual antiplatelet therapy
nd 1 on aspirin only. The incidence of definite or
robable ST was not significantly different between the
roups (0.7% vs. 0.7%, p  0.99).
ROPENSITY-MATCHED POPULATION. There were 54
vents with a median follow-up of 22 months in the
atched patients. With respect to the primary composite
utcome, SES was still associated with a significantly better
utcome in the matched cohort of patients than was PES
Propensity-Matched Population
p Value PES (n  407) SES (n  407) p Value
0.10 0.49
303 (74.4) 305 (74.9)
79 (19.4) 70 (17.2)
25 (6.1) 32 (7.9)
0.22 0.99
294 (72.2) 294 (72.2)
223 (54.8) 210 (51.6)
18 (4.4) 33 (8.1)
53 (13.0) 51 (12.5)
113 (27.8) 113 (27.8)
25 (6.1) 26 (6.4)
34 (8.4) 28 (6.9)
48 (11.8) 54 (13.3)
6 (1.5) 5 (1.2)
0.39 0.85
340 (83.5) 338 (83.0)
67 (16.5) 69 (17.0)
33 (49.3) 36 (52.2)
19 (28.3) 18 (26.1)
13 (19.4) 12 (17.4)
2 (3.0) 3 (4.3)
0.01 168 (41.3) 172 (42.3) 0.78
0.01 105 (25.8) 105 (25.8) 0.99
0.20 18 (4.4) 20 (4.9) 0.74
0.53 114 (28.0) 103 (25.3) 0.38
0.12 30.0 12.2 29.8 12.7 0.76
0.92 3.14 0.32 3.16 0.31 0.53
(n 70) (n 72)
0.18 21.1 7.4 21.3 8.8 0.90
0.02 2.70 0.29 2.75 0.31 0.39
A  right coronary artery; other abbreviations as in Table 1.033)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
.1
1
)
9Table 3, Fig. 2A). Although there were no differences
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April 20, 2010:1743–50 SES and PES in Bifurcation Lesionsetween the 2 groups in the incidence of death or MI,
atients with SES had a significantly lower rate of TLR and
VR compared with patients who had PES (Table 3, Fig.
B). In multivariate analysis, SES was associated with
ignificant reductions in the primary composite outcome
nd TLR (Table 3). The incidence of periprocedural en-
yme elevation and definite or probable ST was similar in
he 2 groups (17.4% in the SES group vs. 16.5% in the PES
roup, p 0.71; and 1.0% in the SES group vs. 0.5% in the
ES group, p  0.41, respectively).
ubgroup analysis. To determine whether the superior
utcomes for SES observed in the overall population were
onsistent, we calculated the unadjusted hazard ratio for
ACE in various complex subgroups (Fig. 3). The rate of
ACE was numerically lower in the SES group than in the
ES group in all subgroups, although statistical significance
as not found in patients with diabetes, non-true bifurca-
ion, or those treated with 2-stent techniques. As shown in
linical Outcomes in Patients Receiving SES Compared With PESTable 3 Clinical Outcomes in Patients Receiving SES Compare
PES SES
Total population (n  1,595) (n 562) (n 1,033)
Cardiac death 2 (0.4) 11 (1.1)
Cardiac death or MI 14 (2.5) 18 (1.7)
TLR 38 (6.8) 38 (3.7)
TVR 47 (8.4) 50 (4.8)
MACE 49 (8.7) 52 (5.0)
Propensity-matched population (n  814) (n 407) (n 407)
Cardiac death 2 (0.5) 6 (1.5)
Cardiac death or MI 8 (2.0) 8 (2.0)
TLR 29 (7.1) 14 (3.4)
TVR 36 (8.8) 20 (4.9)
MACE 35 (8.6) 19 (4.7)
Adjusted covariates included age, sex, acute coronary syndrome, diabetes mellitus, true bifurcatio
iameter, total stent length, and clopidogrel use.
CI  confidence interval; HR  hazard ratio; MACE  major adverse cardiac events; MI  my
bbreviations as in Table 1.
Figure 1 Kaplan-Meier Curves in Patients Receiving SES Versu
(A) Kaplan-Meier curves for major adverse cardiac events (MACE) in the overall po
paclitaxel-eluting stents (PES) (dashed line). (B) Kaplan-Meier curves for target lesigure 3, there were no significant interactions between the
ype of stent and MACE among the 5 subgroups.
iscussion
n the present study, we compared long-term clinical
utcomes after implantation of SES or PES for the treat-
ent of coronary bifurcation lesions in the largest dedicated
ifurcation registry data to date. The main findings of this
tudy were: 1) SES implantation was associated with a lower
ncidence of MACE than was PES implantation, driven
ainly by the lower incidence of TLR; and 2) there was no
ifference in the rates of cardiac death, MI, or ST between
he 2 groups.
Coronary bifurcation lesions are 1 of the most challeng-
ng lesion subsets and are known to have lower angiographic
uccess rates and a higher risk of procedural complications
ith a greater restenosis rate than are nonbifurcation le-
h PES
justed HR (95% CI) p Value Adjusted HR* (95% CI) p Value
.01 (0.67–13.64) 0.26 2.77 (0.40–18.99) 0.62
.69 (0.34–1.41) 0.62 0.97 (0.38–2.49) 0.94
.53 (0.33–0.84) 0.01 0.55 (0.31–0.97) 0.02
.56 (0.37–0.84) 0.01 0.58 (0.38–0.90) 0.02
.56 (0.37–0.83) 0.01 0.53 (0.32–0.89) 0.01
.03 (0.61–15.10) 0.29 2.32 (0.44–12.17) 0.32
.00 (0.37–2.69) 0.99 0.89 (0.33–2.41) 0.82
.46 (0.24–0.89) 0.02 0.48 (0.25–0.91) 0.02
.53 (0.30–0.94) 0.03 0.55 (0.32–0.95) 0.03
.52 (0.29–0.93) 0.02 0.52 (0.30–0.91) 0.02
ting techniques, final kissing ballooning, use of intravascular ultrasound, type of stent used, stent
l infarction; TLR  target lesion revascularization; TVR  target vessel revascularization; other
n receiving sirolimus-eluting stents (SES) (solid line) versus
vascularization (TLR) in the overall population receiving SES versus PES.d Wit
Unad
3
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SES and PES in Bifurcation Lesions April 20, 2010:1743–50ions, even in the DES era (14,15). Considering that
ifurcation lesions are frequent in real-world practice (16), it
s very important to investigate which DES is most effective
n treating bifurcation lesions. However, there are limited
ata regarding comparisons among DES in bifurcation
esions. Although 3 previous studies were performed com-
aring the clinical outcomes of patients treated with SES
ersus PES for bifurcation lesions, all of these studies were
ctually underpowered for the determination of clinical end
oints. Moreover, the data from these studies were conflict-
ng, with 2 studies demonstrating significantly lower TLR
ates for SES compared with PES (8,9) and the other
howing no differences between the 2 stents (10). Therefore,
e compared the long-term clinical outcomes after PCI
ith the 2 most widely available DES, SES, and PES, using
Figure 2 Kaplan-Meier Curves in Propensity-Matched Patients
(A) Kaplan-Meier curves for major adverse cardiac events (MACE) in propensity-ma
paclitaxel-eluting stents (PES) (dashed line). (B) Kaplan-Meier curves for target les
Figure 3 Comparative Unadjusted Hazard Ratios of MACE for S
ACS  acute coronary syndrome; CI confidence interval; MACE  major adversehe COBIS registry. This nationwide multicenter registry is
olely dedicated to bifurcation lesions treated with DES; it
s the largest registry for coronary bifurcation lesions to date.
road indication may make it possible to reflect real-world
ractice and outcomes regarding PCI on bifurcation lesions.
ll baseline and procedural cine coronary angiograms were
eviewed at the angiographic core laboratory and patients
ere thoroughly monitored.
In this study, we demonstrated that SES was more
ffective in improving long-term outcomes than was PES,
rimarily by decreasing repeat revascularization. Patients
ith PES have shown comparable clinical outcomes to
hose with SES in several studies (5–7), but the latter DES
ay be superior to the former in complex lesion subsets
17–19). Considering the complexity of bifurcation lesions,
iving SES Versus PES
patients receiving sirolimus-eluting stents (SES) (solid line) versus
vascularization (TLR) in propensity-matched patients receiving SES versus PES.
ups
c events; PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s).Rece
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April 20, 2010:1743–50 SES and PES in Bifurcation Lesionsur results that SES decrease adverse outcomes seem to be
elevant. However, the rates of cardiac death or MI were not
ignificantly different between patients with SES and pa-
ients with PES. More potent inhibition of neointimal
rowth with SES than with PES may be translated into
eduction of TLR in bifurcation lesions (4), but not into
eath or MI. In the present study, some baseline clinical and
rocedural characteristics were unfavorable in the PES
roup compared with those in the SES group: a higher
revalence of diabetes mellitus and acute coronary syndrome
n admission; smaller stents in the side branch; and less
requent use of IVUS and final kissing balloon inflation.
hese factors may contribute to differences in adverse
utcomes between SES and PES. However, we performed
arious adjustments including propensity score-matching to
djust for the differences in baseline characteristics between
he groups, and the result was consistent in all patients and
ropensity-matched populations.
Across various subgroups, SES consistently showed
etter outcomes compared with those of PES. However,
he superiority of SES was not statistically significant in
atients with diabetes. There is some controversy regard-
ng the efficacies of SES and PES in diabetic patients.
lthough SES had better outcomes than did PES in
erms of late loss and angiographic restenosis in a
andomized study (3), some registries have reported
onflicting results on clinical outcomes (7,20), and a
ecent meta-analysis showed no differences in clinical
utcomes between SES and PES in diabetic patients
21). Among diabetic patients, PES may be comparable
o SES in bifurcation lesions, in contrast to patients
ithout diabetes. However, no interaction was found
etween the type of DES and diabetes. Statistical signif-
cance was not found in patients treated with 2 stents,
ither. However, there was no interaction between the
ype of DES and stent technique. Our results may be
imply attributable to a relatively small numbers of
atients with diabetes or those treated with the 2-stent
echnique. Numerical differences were similar, and the
endency toward SES was consistent across all subgroups.
tudy limitations. Our study had several limitations,
ncluding the fact that it was a nonrandomized, observa-
ional design, which may have significantly affected the
esults because of confounding factors. The selection of
reatment strategies and stent types were at the discretion
f the operators. Although we performed various risk-
djusted and propensity score-matched analyses to adjust
or these potential confounding factors, we were not able
o correct for the unmeasured variables and adjustment by
ropensity score resulted in a reduction of the original
opulation with subsequent loss of statistical power.
oreover, we used many variables to reduce treatment
election bias for potential confounding in observational
tudy, and the overfitting problems that this would
ncrease are the limitations of this study. Our findings
hould be confirmed by adequately powered, randomizedrials. Another limitation is that systemic angiographic
ollow-up was not performed, and coronary angiography
as analyzed qualitatively, not quantitatively. Detailed
uantitative coronary analysis may be helpful in further
nterpreting our findings.
onclusions
he present study showed that SES implantation for the
reatment of coronary bifurcation lesions resulted in a
ignificantly reduced risk of MACE mainly driven by
ecreased TLR without a significant difference in cardiac
eath or MI compared with PES implantation.
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